# LYB earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/LYB) · [Earnings tab](https://www.lopjlb.com/stock/LYB?tab=earnings)

Updated: 2026-08-01T05:51:09

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards, LyondellBasell’s narrative shifts from early‑stage portfolio reshaping and modest cash‑conversion gains to a disciplined transformation anchored by aggressive cash‑improvement, European divestitures and cost‑advantage projects. In 2024 the company highlighted MoReTec‑1 progress, a pending Houston refinery shutdown and a broad European asset review while reporting strong EBITDA growth. 2025 introduced a cash‑improvement plan, Flex‑2 FID and rising capex pressures, but also saw the first signs of earnings volatility and tariff‑related demand uncertainty. Mid‑year the firm began trimming capital, deferring MoReTec‑2 and Flex‑2, and accelerating European asset sales, which culminated in a completed four‑asset divestiture by mid‑2026. 2026 quarters emphasize a lasting cost‑curve shift from Middle‑East supply disruptions, a disciplined $269 M capex, a 50 % dividend cut, and the on‑track launch of MoReTec‑1 (2027) and VEP cost‑reduction. Safety records improve, while supply‑chain and geopolitical risks surface as new concerns. Overall, cash conversion improves dramatically, margins remain pressured, and the company pivots toward a leaner, U.S.–focused portfolio with incremental cash‑flow targets despite lingering market volatility.

## Latest CallCard · Q2

LYB Q2 EBITDA $2.1B (23% margin) driven by Middle East supply disruption; portfolio transformation advancing with 4 European asset divestitures, Brindisi closure; cash improvement plan on track for $500M incremental cash flow; MoReTec 1 on track for 2027 start-up; Bayport restart completed; acetyls 

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** LYB Q2 EBITDA $2.1B (23% margin) driven by Middle East supply disruption; portfolio transformation advancing with 4 European asset divestitures, Brindisi closure; cash improvement plan on track for $500M incremental cash flow; MoReTec 1 on track for 2027 start-up; Bayport restart completed; acetyls 
- **2026 Q1:** LYB sees a lasting cost‑curve shift from the Middle East war, pushes U.S. capacity, completes a European asset sale and targets $500M incremental cash flow while navigating supply constraints and modest Q2 operating‑rate improvements.
- **2025 Q4:** LYB navigates deep cyclical downturn with record safety, $800M cash improvement outperformance, VEP extended to $1.5B by 2028, but delays growth projects; European divestiture on track for Q2'26. Margins 45% below historical averages. No formal EBITDA guidance. Dividend reviewed by Board in Feb. Cap
- **2025 Q3:** LYB reports strong 135% cash conversion, $600M cash improvement plan on track, PE demand inflecting positively but capacity overhang persists; European asset sale progressing, 2026 CapEx cut to $1.2B, dividend security questioned at 12% yield.','tone':{'mgmt':0.3,'mgmt_rationale':'Management highlig
- **2025 Q2:** LYB Q2 EBITDA $715M, EPS $0.62; cash improvement plan raised to $600M for 2025, CapEx cut to $1.7B; Flex-2 and MoReTec-2 deferred; European asset sale on track; safety record strong.','tone': {'mgmt': 0.1, 'mgmt_rationale': 'Management emphasizes safety leadership, strategic portfolio repositioning 
- **2025 Q1:** LYB Q1 EBITDA ~$600M hit by Channelview turnaround; $500M cash improvement plan launched; Flex-2 FID reached; European strategic review update by mid-year; tariff uncertainty clouds demand visibility.','tone': {'mgmt': 0.2, 'mgmt_rationale': 'Management acknowledges challenging, prolonged downturn b
- **2024 Q4:** LYB reports Q4 EPS $6.40, EBITDA $4.3B, 90% cash conversion; VEP run-rate >$800M targeting $1B; CLCS volumes +65% to 200k tons; MoReTec Germany progressing; NATPET expansion; European asset review ongoing; Q1 PE price increases announced amid cracker outages.','tone': {'mgmt': 0.3, 'mgmt_rationale':
- **2024 Q3:** LYB Q3 EBITDA $1.2B, EPS $1.88; O&P Americas strong, refining loss; advancing MoReTec-1 in Germany, Houston refinery closure Q1'25, European asset review underway, targeting cost-advantaged portfolio growth to 70% by 2025.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlighted strong opera

## Theme arcs

- **Cash improvement plan** (improving): Cash conversion rose to 135% and incremental cash‑flow target of $500 M is on track
- **European asset divestiture** (improving): Four assets sold by Q2 2026, completing the strategic review
- **MoReTec projects** (stable): MoReTec‑1 construction on track for 2027 start‑up; MoReTec‑2 deferred
- **Capital discipline** (improving): CapEx cut from $1.7 B to $1.2 B then to $269 M
- **Margins** (deteriorating): Margins 45 % below historical averages, though cost‑advantage from ethane feedstock noted
- **Dividend policy** (deteriorating): Dividend cut 50 % and board review in 2025‑26
- **Demand visibility** (resolved): Tariff uncertainty noted in Q1 2025 but not mentioned later
- **Safety performance** (improving): Record safety highlighted in 2025‑26 calls
- **Supply‑chain/geopolitical risk** (new): Explicitly flagged in 2026 Q1 as a recurring concern

## Fear persistence

- **Geopolitical risk (Middle East war)** [new]: First flagged in 2026 Q1 as affecting crude risk premium
- **Supply‑chain disruption** [new]: Highlighted in 2026 Q1 with potential for prolonged outages
- **Demand destruction (price‑driven)** [new]: Noted risk if polyethylene prices rise sharply
- **Pricing volatility** [new]: Creates margin uncertainty across regions
- **Asset outages** [new]: Bayport and La Porte delays cited as limiting market capture
- **Tariff uncertainty** [resolved]: Mentioned in 2025 Q1, absent in later calls
- **Capacity overhang** [resolved]: Cited in 2025 Q3, not referenced thereafter

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/LYB`